Skip to main content
Top
Published in: Endocrine Pathology 1/2009

01-03-2009

Invasive Giant Prolactinoma with Loss of Therapeutic Response to Cabergoline: Expression of Angiogenic Markers

Authors: María Susana Mallea-Gil, Carolina Cristina, María Inés Perez-Millan, Ana M. Rodriguez Villafañe, Carolina Ballarino, Graciela Stalldecker, Damasia Becu-Villalobos

Published in: Endocrine Pathology | Issue 1/2009

Login to get access

Abstract

The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle. Patient was initially responsive to cabergoline with reduction of prolactin levels and shrinkage of tumor burden for at least 36 months. Thereafter, prolactin levels and tumor size increased even though cabergoline dosage was increased. Transcraneal surgery was performed at 56 months of treatment. Prolactin levels and tumor proliferation did not subside and the patient died 14 months later. High GH and IGF-I levels were observed in the late stages of tumor development, with no evidence of acromegalic features. Immunohistochemistry of the excised tumor revealed strong immunoreactivity for VEGF and FGF-2, two potent angiogenic factors, and CD31 (an endothelial marker) indicating high vascularization of the adenoma.
Literature
6.
go back to reference McCall D, Hunter SJ, Cooke RS, Herron B, Sheridan B, Atkinson AB. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clin Endocrinol (Oxf) 66:149–50, 2007. McCall D, Hunter SJ, Cooke RS, Herron B, Sheridan B, Atkinson AB. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clin Endocrinol (Oxf) 66:149–50, 2007.
8.
go back to reference Mucha SA, Melen-Mucha G, Godlewski A, Stepien H. Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Arch 450:335–41, 2007. doi:10.1007/s00428-006-0351-x.PubMedCrossRef Mucha SA, Melen-Mucha G, Godlewski A, Stepien H. Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Arch 450:335–41, 2007. doi:10.​1007/​s00428-006-0351-x.PubMedCrossRef
9.
go back to reference Pawlikowski M, Grochal M, Kulig A, Zielinski K, Stepien H, Kunert-Radek J, et al. The effect of angiotensin II receptor antagonists on diethylstilbestrol-induced vascular changes in the rat anterior pituitary gland: a quantitative evaluation. Histol Histopathol 11:909–13, 1996. Pawlikowski M, Grochal M, Kulig A, Zielinski K, Stepien H, Kunert-Radek J, et al. The effect of angiotensin II receptor antagonists on diethylstilbestrol-induced vascular changes in the rat anterior pituitary gland: a quantitative evaluation. Histol Histopathol 11:909–13, 1996.
10.
go back to reference Stepien H, Grochal M, Zielinski KW, Mucha S, Kunert-Radek J, Kulig A, et al. Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. J Endocrinol 150:99–106, 1996. doi:10.1677/joe.0.1500099.PubMedCrossRef Stepien H, Grochal M, Zielinski KW, Mucha S, Kunert-Radek J, Kulig A, et al. Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. J Endocrinol 150:99–106, 1996. doi:10.​1677/​joe.​0.​1500099.PubMedCrossRef
15.
go back to reference Komorowski J, Jankewicz J, Stepien H. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours. Cytobios 101:151–9, 2000.PubMed Komorowski J, Jankewicz J, Stepien H. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours. Cytobios 101:151–9, 2000.PubMed
16.
17.
go back to reference Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low MJ, et al. Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 146:2952–62, 2005. doi:10.1210/en.2004-1445.PubMedCrossRef Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low MJ, et al. Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 146:2952–62, 2005. doi:10.​1210/​en.​2004-1445.PubMedCrossRef
21.
go back to reference Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res 38:84–9, 1992.PubMedCrossRef Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res 38:84–9, 1992.PubMedCrossRef
22.
23.
go back to reference Maraschini C, Moro M, Masala A, Toja P, Alagna S, Brunani A, et al. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol (Copenhagen) 125:494–501, 1991. Maraschini C, Moro M, Masala A, Toja P, Alagna S, Brunani A, et al. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol (Copenhagen) 125:494–501, 1991.
25.
go back to reference Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314–22, 1994. doi:10.1159/000126764.PubMedCrossRef Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314–22, 1994. doi:10.​1159/​000126764.PubMedCrossRef
27.
go back to reference Schechter J, Goldsmith P, Wilson C, Weiner R. Morphological evidence for the presence of arteries in human prolactinomas. J Clin Endocrinol Metab 67:713–9, 1988.PubMed Schechter J, Goldsmith P, Wilson C, Weiner R. Morphological evidence for the presence of arteries in human prolactinomas. J Clin Endocrinol Metab 67:713–9, 1988.PubMed
28.
go back to reference Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocr Pathol 6:115–24, 1995. doi:10.1007/BF02739874.PubMedCrossRef Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocr Pathol 6:115–24, 1995. doi:10.​1007/​BF02739874.PubMedCrossRef
29.
go back to reference Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229–35, 1999. doi:10.1007/BF02738884.PubMedCrossRef Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229–35, 1999. doi:10.​1007/​BF02738884.PubMedCrossRef
30.
go back to reference McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–44, 2002. doi:10.1210/jc.2002-020309.PubMedCrossRef McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–44, 2002. doi:10.​1210/​jc.​2002-020309.PubMedCrossRef
31.
go back to reference Arita K, Kurisu K, Tominaga A, Sugiyama K, Eguchi K, Hama S, et al. Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma. Hiroshima J Med Sci 53:23–7, 2004.PubMed Arita K, Kurisu K, Tominaga A, Sugiyama K, Eguchi K, Hama S, et al. Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma. Hiroshima J Med Sci 53:23–7, 2004.PubMed
32.
go back to reference Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569–74, 2001. doi:10.1038/87895.PubMedCrossRef Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569–74, 2001. doi:10.​1038/​87895.PubMedCrossRef
33.
go back to reference Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 10:4349–56, 2004. doi:10.1158/1078-0432.CCR-04-0059.PubMedCrossRef Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 10:4349–56, 2004. doi:10.​1158/​1078-0432.​CCR-04-0059.PubMedCrossRef
34.
go back to reference Cristina C, García-Tornadú I, Diaz-Torga G, Rubinstein M, Low MJ, Becu-Villalobos D. The dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res 35:50–63, 2006. doi:10.1159/000094308.PubMedCrossRef Cristina C, García-Tornadú I, Diaz-Torga G, Rubinstein M, Low MJ, Becu-Villalobos D. The dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res 35:50–63, 2006. doi:10.​1159/​000094308.PubMedCrossRef
35.
go back to reference Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 96:352–60, 2002.PubMedCrossRef Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 96:352–60, 2002.PubMedCrossRef
36.
go back to reference Gurlek A, Karavitaki N, Ansorge O, Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143–53, 2007. doi:10.1530/eje.1.02339.PubMedCrossRef Gurlek A, Karavitaki N, Ansorge O, Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143–53, 2007. doi:10.​1530/​eje.​1.​02339.PubMedCrossRef
37.
go back to reference Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res 35:561–5, 2002.PubMed Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res 35:561–5, 2002.PubMed
Metadata
Title
Invasive Giant Prolactinoma with Loss of Therapeutic Response to Cabergoline: Expression of Angiogenic Markers
Authors
María Susana Mallea-Gil
Carolina Cristina
María Inés Perez-Millan
Ana M. Rodriguez Villafañe
Carolina Ballarino
Graciela Stalldecker
Damasia Becu-Villalobos
Publication date
01-03-2009
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 1/2009
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-009-9057-3

Other articles of this Issue 1/2009

Endocrine Pathology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.